Table 1. Clinical trials on preoperative neoadjuvant therapy for resectable esophageal cancer in which pembrolizumab was involved.

Study	Phase	N	Treatment	pCR (%)	OS (%)	AEs (≥3, %)
PALACE-1	I	20	Pembrolizumab + chemoradiotherapy	55.6	NR	65
NCT02844075	II	28	Pembrolizumab + chemoradiotherapy	46.1	6 mo: 89.3; 12 mo: 80.8; 18 mo: 73.1	NR

N, number; pCR, pathological response rate; AEs, adverse reactions; OS, overall survival; NR, not reported; %, percent; mo, month.